Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Major acquisition still on the table for Pfizer in 2015

This article was originally published in Scrip

Executive Summary

Pfizer "has the capability of undertaking other deals independent of size," CEO Ian Read stated during the company's first quarter results presentation. The US pharma major, which announced the acquisition of Hospira and its biosimilar portfolio for $17bn in February, still has plenty of cash to spend, having walked away from the $100bn-plus buy-out of an unwilling AstraZeneca last year. It is "agnostic" to the size of any acquisition as long as it "moved the needle" and created value for shareholders, added Mr Read.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts